U.S. Government Selects Navitas to Develop Next-Generation 10 kV SiC Power Semiconductors. Shares Up in Pre-Market

Navitas Semiconductor (Nasdaq: NVTS) announced that it has been awarded the ALATTIS (Accelerated, Large-Area, 10 kV SiC IGBT) program to develop next-generation 10 kV silicon carbide (SiC) power semiconductor technology.
Following a competitive evaluation, the U.S. Army selected Navitas for the program, which will focus on developing and validating a domestic manufacturing process for ultra-high-voltage SiC power semiconductor devices through design, fabrication, and testing.
The project is sponsored by the Army Research Laboratory (ARL), under the U.S. Army Combat Capabilities Development Command (DEVCOM), and supported by the Joint Experimentation and Technology Accelerator (JETX). The program aims to advance high-power electronics for critical defense and infrastructure applications, including the development of 10 kV SiC insulated-gate bipolar transistors (IGBTs) and associated PiN diode technologies.
Navitas’ GeneSiC SiC portfolio currently spans voltage ratings from 650 V to 6.5 kV. The company has previously developed 6.5 kV SiC thyristors, 10–15 kV PiN diodes, and commercially released 6.5 kV SiC MOSFETs.
“The ALATTIS award marks a significant milestone in advancing ultra-high-voltage silicon carbide (SiC) power devices,” said Siddarth Sundaresan, SVP and Chief Technology Officer at Navitas.

The program will allow the company to expand beyond SiC MOSFETs into next-generation 10 kV SiC IGBTs using its trench-assisted planar architecture. GlobeNewswire reports.

🧬 AstraZeneca to Invest $2 Billion in Summit Therapeutics for Cancer Drug Tie-Up. Shares Up in Pre-Market
Summit Therapeutics (Nasdaq: SMMT) said on Monday that British drugmaker AstraZeneca will invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments together.
Summit shares rose more than 15% following the announcement. Reuters reports.

🔐 BIO-key Partners with Al Majlis Group to Expand Identity Security Across the Arabian Gulf. Shares Up in Pre-Market
BIO-key International (Nasdaq: BKYI), a provider of identity and access management solutions featuring Identity-Bound Biometrics, announced a strategic partnership with Al Majlis Group, a Dubai-based public affairs and advisory firm.
Under the partnership, BIO-key and Al Majlis Group will work together to introduce BIO-key’s identity security platform to government and private-sector organizations across the UAE and Saudi Arabia.
The collaboration combines Al Majlis Group’s regional expertise and advisory capabilities with BIO-key’s biometric authentication and identity and access management technology. The first phase will focus on jointly approaching a select group of priority organizations across the region. GlobeNewswire reports.

🧪 Silexion Therapeutics Reports Positive Preclinical Findings for SIL204. Shares Up in Pre-Market
Silexion Therapeutics (Nasdaq: SLXN), a clinical-stage biotechnology company developing RNA interference therapies for KRAS-driven cancers, announced positive new findings from an ongoing translational study evaluating the cellular uptake and gene-silencing mechanism of its lead candidate, SIL204.
The study, which supports the company’s Phase 2/3 clinical development program, found that SIL204 can use naturally occurring circulating lipoproteins to enter cells and produce a potent, dose-dependent reduction in mutant KRAS oncogene expression in cancer cells. Globenewswire reports.

🤖 AIxCrypto Holdings (Nasdaq: AIXC, Soon to Trade Under FFR) Signs Term Sheet with Faraday Future to Acquire Its Robotics Business at an Estimated $200 Million Valuation, Aiming to Become the First Nasdaq-Listed Pure-Play Robotics Ecosystem Company

AIxCrypto Holdings (Nasdaq: AIXC) announced that it has entered into a non-binding term sheet with Faraday Future Intelligent Electric (Nasdaq: FFAI) for a proposed all-stock acquisition of Faraday Future’s robotics assets and businesses.
As part of the proposed transaction, AIxCrypto plans to undergo a strategic transformation and will be renamed FF EAI Robotics Ecosystem Inc., with its ticker changing from AIXC to FFR, effective September 30, 2026.
The transaction remains subject to definitive agreements, special committee and stockholder approvals, and other customary closing conditions, and may not be completed. PRNewswire reports.

💻 Sangoma Technologies Corporation Enters into Definitive Agreement to Be Acquired by BRC Group Holdings
Sangoma Technologies Corporation (TSX: STC; Nasdaq: SANG), a provider of on-premises, cloud-based, and hybrid business communications solutions, and BRC Group Holdings (Nasdaq: RILY), a diversified holding company with a business communications portfolio, announced that they have entered into a definitive arrangement agreement.
Under the agreement, an affiliate of BRC will acquire all issued and outstanding common shares of Sangoma in a transaction valuing the company at an enterprise value of approximately US$204 million. Businesswire reports.

(All pricing and percent gains are based on Early Pre-Market from 4:00 AM to 7:00 AM ET). Stock Analysis reports.

1) BKYI: BIO-key International, Inc.
Total gain: +45.24%

2) SANG: Sangoma Technologies Corporation
Total gain: +38.16%

3) YMT: Yimutian Inc.
Total gain: +20.90%

4) MSGY: Masonglory Limited
Total gain: +19.17%

5) SMMT: Summit Therapeutics Inc.
Total gain: +18.22%

The closing price of the top three market percent gainers trading near or above $2 on Sep 28.

(All pricing and percent gains are based on regular market trading hours from 9:30 AM to 4:00 PM ET). Stock Analysis reports.

1) KOD: Kodiak Sciences Inc.
Total gain: +177.96%

The company announced that the primary endpoints were met for both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in the Phase 3 DAYBREAK study in patients with wet age-related macular degeneration (wAMD). The DAYBREAK study in wAMD demonstrated that both Zenkuda and tabirafusp-ted achieved non-inferiority in vision gains compared to aflibercept at year one. StockAnalysis reports.

2) LFCR: Lifecore Biomedical, Inc.
Total gain: +55.24%

The company announced that it has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to $663.7 million, assuming full achievement of certain performance milestones. GlobeNewswire reports.

3) EGG: Enigmatig Limited
Total gain: +51.79%

The stock appeared to be moving on no notable news.

(Estimate and Actual numbers represent Earnings Per Share in US Dollars)

UEC

Uranium Energy

Q4 2026

Before Market Open

Estimate: -0.020

Actual: -0.120

KMX

CarMax

Q2 2027

Before Market Open

Estimate: 0.700

Actual: 1.160

CCL

Carnival

Q3 2026

Before Market Open

Estimate: 1.350

Actual: N/A

Time (ET) / Report / Period

• 9:00 AM / S&P Cotality Case-Shiller Home Px Index / Jul.
• 10:00 AM / Conference Bd - Consumer Confidence / Sep
• 10:00 AM / Job Openings & Labor Turnover Survey / Aug.

“For investors as a whole, returns decrease as motion increases.”

– Warren Buffett

Sourced in: Berkshire Hathaway 2005 Annual Letter.

TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas ; TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF); and TradeZero Europe B.V., a Dutch broker dealer, authorized and regulated by the Dutch Authority for the Financial Markets (AFM) (collectively, the “TradeZero Broker Dealers”).

TradeZero Broker Dealers offer self-directed electronic securities trading to their customers. TradeZero Broker Dealers do not provide financial or trading advice and do not make investment recommendations to their customers. This communication does not constitute an offer to sell or a solicitation to buy any security or instrument which it may reference.

The information in this newsletter summarizes the latest market activity and related news and are provided for educational purposes only. Any trading symbols displayed are for illustrative purposes only and do not constitute a recommendation by TradeZero to buy, sell, or hold any investment. This material is not intended to provide investment advice or to take into account any individual’s financial condition, investment objectives, or requirements.

Investing involves risk, including the possible loss of principal.

There is a risk of loss in online trading of securities including equities and options. Trading on margin is for experienced investors whereby the loss can be greater than your initial investment. Likewise, short selling as a securities trading strategy is extremely risky and can lead to potentially unlimited losses.

Options trading is not suitable for all investors as it can involve risk that may expose investors to significant losses. Please read the Characteristics and Risks of Standardized Options, also known as the Options Disclosure Document (ODD) at OCC.

Stocks experiencing significant price volatility may involve substantial risk. Past performance is no guarantee of future results.

Any trading strategies discussed are for educational purposes only and should not be construed as investment advice or a recommendation.

Certain information herein has been obtained from third-party sources believed to be reliable; however, its accuracy or completeness cannot be guaranteed. The views and opinions expressed are those of the author and do not necessarily reflect the views or opinions of TradeZero, its affiliates, or employees.

If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero Broker Dealer servicing your jurisdiction.

Copyright © TradeZero 2026. All rights reserved.